Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Studyopen access
- Authors
- Roh, Sungwon; Lee, Kang Soo; Choi, Songhwa; Kim, Jae-Min
- Issue Date
- Aug-2022
- Publisher
- KOREAN COLL NEUROPSYCHOPHARMACOLOGY
- Keywords
- Desvenlafaxine; Safety; Treatment outcome; Antidepressant; Major depressive disorder; Korea
- Citation
- CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.20, no.3, pp.548 - 559
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
- Volume
- 20
- Number
- 3
- Start Page
- 548
- End Page
- 559
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171524
- DOI
- 10.9758/cpn.2022.20.3.548
- ISSN
- 1738-1088
- Abstract
- Objective: Although the safety and efficacy of desvenlafaxine have been demonstrated, long-term evidence in Asians is lacking. We examined the safety and effectiveness of desvenlafaxine for up to 6 months in routine clinical practice in Korea. Methods: This multicenter, open-label, prospective observational study was conducted from February 2014 to February 2020 as a postmarketing surveillance study of desvenlafaxine (ClinicalTrials.gov identifier: NCT02548949). Adult patients with major depressive disorder (MDD) were observed from the initiation of treatment for 8 weeks (acute treatment phase) and then up to 6 months (continuation treatment phase) in a subsample. Safety was evaluated by incidence of adverse events (AE) and adverse drug reactions. Treatment response was assessed using the Clinical Global ImpressionResults: We included 700 and 236 study subjects in the analysis of acute and continuation treatment phase, respectively. In acute treatment phase, AE incidence was 9.86%, with nausea being most common (2.00%). In continuation treatment phase, AE incidence was 2.97%, with tremor occurring most frequently. After acute treatment (n = 464), the treatment response rate according to the CGI-I score at week 8 was 28.9%. In long-term users (n = 213), the response rate at month 6 was 45.5%. During the study period, no clinically relevant changes in BP were found regardless of concomitant use of antihypertensive drugs. Conclusion: This study provides evidence on the safety and effectiveness of desvenlafaxine in adults with MDD, with a low incidence of AE, consistent AE profile with previous studies, and improved response after long-term treatment.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 정신건강의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171524)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.